Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:47 PM
Ignite Modification Date:
2025-12-24 @ 9:47 PM
NCT ID:
NCT03123432
Eligibility Criteria:
Inclusion Criteria:
* Age between 20-85 years old
* Histologically proven primary gastric cancer or GIST.
* Patients was planning to receive elective curative gastric surgery, such as partial gastrectomy, subtotal gastrectomy, proximal gastrectomy, total gastrectomy, etc.
* Patient is able to understand the requirements of the study and written informed consent was obtained from each subject.
Exclusion Criteria:
* They were less than 20 years or over 85 years old
* Hepatic dysfunction or bile stasis (serum total bilirubin \>2.5 mg/dL)
* Renal dysfunction (serum creatinine \>1.5 mg/dL), or required hemodialysis
* Cardiac dysfunction (NYHA functional class \>III, or stroke history)
* Severe hypoalbuminemia (albumin \<2.5 g/dL)
* Karnofsky performance status less than 60
* Overweight (body mass index \[BMI\] \>30 kg/m2)
* Exhibited drug abuse or chronic alcoholism
* Had life-threatening disease, or underwent emergent surgery
* With infection or bowel obstruction
* Pregnant or lactating
* Had received chemotherapy within 14 days of the initiation of the trial
* Had received immunosuppressive therapy or had immunological diseases recently
* Had already participated in another clinical study with an investigational drug or an investigational medical device within a month of the initiation or during the study
* Hypersensitive to casein, fish oil, soybean, or corn oil
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Maximum Age:
85 Years
Study:
NCT03123432
Study Brief:
Protocol Section:
NCT03123432